A patient with agranulocytosis following the discontinuation of methimazole treatment for 4 months: A case report
- Authors:
- Xiao‑Su Bai
- Jing‑Hai Liu
- Shao‑Mei Xiao
View Affiliations
Affiliations: Department of Metabolism and Endocrinology, People's Hospital Of New District Longhua Shenzhen, Shenzhen, Guangdong 518109, P.R.China
- Published online on: June 30, 2014 https://doi.org/10.3892/etm.2014.1817
-
Pages:
823-825
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Agranulocytosis is a rare and serious adverse effect of antithyroid drugs (ATD), in particular methimazole (MMI), and usually develops within 3 months following the start of uninterrupted ATD treatment. Agranulocytosis may also develop for the first time following interruption and subsequent resumption of the same ATD treatment. In this case report, a 27‑year‑old female, who was treated for thyrotoxicosis with MMI, developed agranulocytosis following the discontinuation of MMI treatment for four months. To the best of our knowledge, this is the first study to report this. The aim of this report is to increase the awareness of physicians of the onset of agranulocytosis when MMI is discontinued, and to demonstrate that MMI should be used with caution.
View References
|
1
|
Andres E, Dali-Youcef N, Serraj K and
Zimmer J: Recognition and management of drug-induced
blood-cytopenias: the example of idiosyncratic drug-induced
thrombocytopenia. Expert Opin Drug Saf. 8:183–190. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tajiri J and Noguchi S: Antithyroid
drug-induced agranulocytosis: special reference to normal white
blood cell count agranulocytosis. Thyroid. 14:459–462. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tamai H, Takaichi Y, Morita T, Komaki G,
et al: Methimazole-induced agranulocytosis in Japanese patients
with Graves’ disease. Clin Endocrinol (Oxf). 30:525–530. 1989.
|
|
4
|
Waldhauser L and Uetrecht J: Oxidation of
propylthiouracil to reactive metabolites by activated neutrophils.
Implications for agranulocytosis. Drug Metab Dispos. 19:354–359.
1991.PubMed/NCBI
|
|
5
|
Pisciotta AV: Immune and toxic mechanisms
in drug-induced agranulocytosis. Semin Hematol. 10:279–310.
1973.PubMed/NCBI
|
|
6
|
Wall JR, Fang SL, Kuroki T, Ingbar SH and
Braverman LE: In vitro immunoreactivity to propylthiouracil,
methimazole, and carbimazole in patients with Graves’ disease: a
possible cause of antithyroid drug-induced agranulocytosis. J Clin
Endocrinol Metab. 58:868–872. 1984.PubMed/NCBI
|
|
7
|
Toth EL, Mant MJ, Shivji S and Ginsberg J:
Propylthiouracil induced agranulocytosis: an unusual presentation
and a possible mechanism. Am J Med. 85:725–727. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sprikkelman A, de Wolf JT and Vellenga E:
The application of hematopoietic growth factors in drug-induced
agranulocytosis: a review of 70 Cases. Leukemia. 8:2031–2036.
1994.PubMed/NCBI
|
|
9
|
Sun MT, Tsai CH and Shih KC: Antithyroid
drug-induced agranulocytosis. J Chin Med Assoc. 72:438–441. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Akamizu T, Ozaki S, Hiratani H, et al:
Drug-induced neutropenia associated with anti-neutrophil
cytoplasmic antibodies (ANCA): possible involvement of complement
in granulocyte cytotoxicity. Clin Exp Immunol. 127:92–98. 2002.
View Article : Google Scholar
|
|
11
|
Harper L, Chin L, Daykin J, et al:
Propylthiouracil and carbimazole associated- antineutrophil
cytoplasmic antibodies (ANCA) in patients with Graves’ disease.
Clin Endocrinol (Oxf). 60:671–675. 2004.
|
